Interleukin-5 Antagonist Monoclonal Antibody Therapy Improves Symptoms and Reduces Steroid Dependence in Eosinophilic Myocarditis Patients

Interleukin-5 Antagonist Monoclonal Antibody Therapy Improves Symptoms and Reduces Steroid Dependence in Eosinophilic Myocarditis Patients

Eosinophilic myocarditis (EM) is a rare disease associated with significant morbidity and mortality. This case series follows the clinical courses of 3 patients with EM. The use of mepolizumab, an anti–interleukin-5 monoclonal antibody, as an adjunctive treatment was associated with stabilization of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JACC. Case reports 2024-04, Vol.29 (7), p.102267, Article 102267
Hauptverfasser: Trovato, Vincenzo, Asada, Ashlee, Fussner, Lynn, Curtis, Casey, Kahwash, Rami
Format: Artikel
Sprache:eng
Schlagworte:
eosinophilic myocarditis
interleukin-5
myocarditis
reduced ejection fraction
steroid-sparing
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Eosinophilic myocarditis (EM) is a rare disease associated with significant morbidity and mortality. This case series follows the clinical courses of 3 patients with EM. The use of mepolizumab, an anti–interleukin-5 monoclonal antibody, as an adjunctive treatment was associated with stabilization of cardiac function and improved long-term outcomes. [Display omitted]
ISSN:2666-0849
2666-0849
DOI:10.1016/j.jaccas.2024.102267